振德医疗(603301) - 2021 Q3 - 季度财报

Financial Performance - Revenue for Q3 2021 was CNY 950,542,476.87, a decrease of 77.88% compared to the same period last year[7] - Net profit attributable to shareholders for Q3 2021 was CNY 104,325,942.71, down 90.59% year-on-year[7] - Basic earnings per share for Q3 2021 was CNY 0.46, a decline of 91.40% compared to the previous year[9] - Revenue for the year-to-date period was CNY 3,862,648,045.72, down 52.41% year-on-year[7] - Net profit attributable to shareholders for the year-to-date period was CNY 482,529,812.69, a decrease of 77.00% compared to the previous year[7] - Total operating revenue for the first three quarters of 2021 was CNY 3,862,648,045.72, a decrease from CNY 8,116,660,488.11 in the same period of 2020, representing a decline of approximately 52.3%[26] - Net profit for the first three quarters of 2021 was CNY 585,594,652.61, compared to CNY 2,409,971,170.87 in 2020, reflecting a decrease of approximately 75.7%[33] - The total comprehensive income attributable to the parent company for the first three quarters of 2021 is CNY 482,529,812.69, compared to CNY 2,097,753,320.69 in the same period of 2020, indicating a significant decrease[35] Assets and Liabilities - Total assets as of the end of Q3 2021 were CNY 6,782,938,953.56, an increase of 5.98% from the end of the previous year[9] - The company's total assets as of September 30, 2021, are approximately ¥6.78 billion, compared to ¥6.40 billion at the end of 2020[24] - The company's total liabilities amounted to CNY 2,465,310,794.24, an increase from CNY 1,933,193,883.17 in the previous year, showing a growth of about 27.5%[26] - The total liabilities increased to approximately ¥2.10 billion from ¥1.74 billion year-over-year[24] - Current liabilities reached approximately $1.74 billion, remaining unchanged from the previous period[47] - Total liabilities were approximately $1.93 billion, down by $62.66 million compared to the previous period[47] Cash Flow - Cash flow from operating activities for the year-to-date period decreased by 80.76% to CNY 514,487,076.18[9] - Net cash flow from operating activities for the first three quarters of 2021 is CNY 514,487,076.18, a decrease from CNY 2,673,731,914.25 in the same period of 2020[39] - Cash inflow from operating activities totaled CNY 4,534,671,652.40 in the first three quarters of 2021, compared to CNY 8,968,332,752.97 in the same period of 2020[39] - The company reported a net increase in cash and cash equivalents of CNY 190,195,182.89 for the first three quarters of 2021, compared to an increase of CNY 1,321,802,813.74 in the same period of 2020[39] Shareholder Information - The total number of common shareholders at the end of the reporting period is 46,055[15] - Zhejiang Zhend Medical Holdings Co., Ltd. holds 48.06% of the shares, making it the largest shareholder[15] - The top ten shareholders collectively hold 83.50% of the shares, indicating a high level of concentration[17] - The company has no preferred shareholders with restored voting rights[15] Operational Costs and Expenses - Total operating costs for the first three quarters of 2021 were CNY 3,257,979,534.49, down from CNY 5,206,925,389.74 in 2020, indicating a reduction of about 37.4%[29] - Research and development expenses for the first three quarters of 2021 were CNY 105,536,290.91, compared to CNY 166,626,599.77 in 2020, a reduction of about 36.6%[29] - The company reported a profit from operations of CNY 668,686,550.96, significantly lower than CNY 2,899,823,827.82 in the same period of 2020, a decline of approximately 77.0%[31] - The company’s financial expenses decreased to CNY 5,716,071.15 from CNY 48,082,599.43, a reduction of approximately 88.1%[29] Market Conditions - The decline in revenue and profit was attributed to the normalization of prices for pandemic-related protective products and increased shipping costs due to global supply chain issues[11] Other Financial Metrics - The weighted average return on equity decreased by 34.76 percentage points to 2.63% in Q3 2021[9] - The company's cash and cash equivalents as of September 30, 2021, amount to approximately ¥1.95 billion, an increase from ¥1.81 billion at the end of 2020[21] - Total current assets decreased to approximately ¥3.73 billion from ¥4.35 billion year-over-year[21] - Short-term borrowings increased to approximately ¥646.84 million from ¥358.37 million year-over-year[24] - The company reported a decrease in inventory to approximately ¥821.55 million from ¥1.08 billion year-over-year[21] - The company’s deferred income tax liabilities increased to CNY 37,619,757.21 from CNY 7,855,497.98, indicating a growth of about 377.5%[26] - The company adopted new leasing standards effective January 1, 2021, impacting the accounting treatment of lease liabilities and right-of-use assets[48]